Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00451113
Status:
COMPLETED
Last Update Posted:
2018-01-18
First Post:
2007-03-21
Brief Title:
Sitagliptin in the Elderly
Sponsor:
University of British Columbia
Organization:
University of British Columbia
Study Overview
Official Title:
Sitagliptin in the Elderly
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Diabetes is common in the elderly by the age of 70 approximately 25 of the population will have diabetes Unfortunately currently available medications are often not as effective or not well tolerated in older adults Sitagliptin is a new medication in a new class of agent called incretins Incretins have many potential advantages for the treatment of diabetes in the elderly They stimulate insulin secretion which is impaired in all older people with diabetes The incidence of hypoglycemia with currently available medications increases with age and incretins rarely cause hypoglycemia They assist with weight loss whereas many current medications used to manage diabetes result in weight gain in the elderly They improve insulin action and insulin resistance is a major problem in older people with diabetes
Detailed Description:
To date no clinical trials have been conducted specifically in the elderly but the data noted above from our laboratory would imply that inhibitors of this enzyme could be more effective in the elderly patient population In addition we have convincingly demonstrated that diabetes in the elderly is metabolically distinct from diabetes in middle aged patients 1 Thus it is clear further studies are warranted to determine the effectiveness of drugs in this class in elderly patients with diabetes We propose a series of studies with your DP4 inhibitor sitaglipitin to determine its efficacy and safety in an elderly patient population with diabetes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None